Hepatitis
MONDO:0002251An active inflammatory process affecting the liver for more than six months. Causes include viral infections, autoimmune disorders, drugs, and metabolic disorders.
Also known as: Hepatitis, hepatitis, inflammation of liver, liver inflammation, acute and subacute liver necrosis, acute hepatitis, acute/subac. necrosis of liver, animal hepatitis
731 clinical trials for this condition and its sub-types, 50 tagged with Hepatitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hepatitis
-
Viral hepatitis 12 trials · 443 incl. sub-types
6 sub-types
- Hepatitis B virus infection 251 trials · 274 incl. sub-types Sub-types →
- Hepatitis C virus infection 158 trials · 162 incl. sub-types Sub-types →
- Hepatitis D virus infection 47 trials
- Hepatitis A virus infection 10 trials
- Hepatitis E virus infection 5 trials
- Epstein-Barr virus hepatitis 0 trials
-
Alcoholic hepatitis 31 trials
-
Autoimmune hepatitis 30 trials · 31 incl. sub-types
7 sub-types
- Autoimmune cholangitis 1 trial
- Autoimmune hepatitis type 1 0 trials
- Autoimmune hepatitis type 2 0 trials
- Autoimmune hepatitis type 3 0 trials
- Giant cell hepatitis with autoimmune hemolytic anemia 0 trials
- Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome 0 trials
- Seronegative autoimmune hepatitis 0 trials
-
Drug-induced hepatitis 3 trials
-
Fulminant viral hepatitis 3 trials
-
Granulomatous hepatitis 0 trials
-
Hepatic tuberculosis 0 trials
-
Idiopathic peliosis hepatis 0 trials
Most studied deeper sub-types
-
Can a Two-Drug combo finally beat chronic hepatitis b?
Cure CompletedThis phase 2 trial is testing whether a combination of two experimental drugs, BRII-835 and BRII-179, can clear the hepatitis B virus from the body in adults with chronic infection. Participants will receive the drug combination and then be monitored to see if they can safely sto…
Phase 2 • Sponsor: Brii Biosciences Limited • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
New drug aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 3 study tests bepirovirsen, an experimental drug, in 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough to allow patients to stop all hepatitis B treatments and remain viru…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to cure hepatitis b without lifelong pills
Disease control CompletedThis Phase 3 trial tests a drug called bepirovirsen in nearly 1,000 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough that participants can safely stop all hepatitis B medications and re…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participan…
Phase 2 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for hepatitis b: experimental combo aims to clear the virus
Disease control CompletedThis study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…
Phase 2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hepatitis b: experimental drug shows promise in mid-stage trial
Disease control CompletedThis study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…
Phase 2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for HIV patients with Hard-to-Treat hepatitis c
Disease control CompletedThis study tested a more intensive hepatitis C treatment in 58 adults who have both HIV and hepatitis C (genotypes 1 or 4) and had not responded to previous therapy. Participants received higher doses of two drugs, peginterferon alfa-2a and ribavirin, for up to 18 months. The goa…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for hepatitis b: experimental combo aims to silence the virus
Disease control CompletedThis early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…
Phase 1/2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
No-Needle liver test: MRI may replace painful biopsies
Diagnosis CompletedThis study tested a new, fully automated MRI technique to diagnose liver fibrosis and inflammation without needing a needle biopsy or contrast dye. Researchers scanned 200 adults with chronic liver disease and compared the MRI results to standard biopsy findings. The goal is to p…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
Blood safety watch: 1,771 transfusion patients tracked for hidden infections
Knowledge-focused CompletedThis study followed 1,771 adults and children who received blood transfusions to check how safe the blood supply is. Researchers tested patients' blood for viruses like HIV and hepatitis before and after transfusion, and stored samples for future testing. The goal was to keep blo…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Prison TB study tests shorter prevention course
Knowledge-focused CompletedThis study looked at ways to prevent tuberculosis (TB) in Malaysian prisoners, many of whom also had HIV, opioid addiction, or hepatitis. Researchers compared a standard 40-week TB prevention treatment with a shorter 12-week option. The goal was to see which approach worked bette…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Study links vaginal germs to preterm birth risk
Knowledge-focused CompletedThis study followed 603 pregnant women in South Africa to see if infections or bacteria in the vagina are linked to how early they give birth. Researchers tested for sexually transmitted infections, yeast, and other germs at the start of pregnancy and again at 30-34 weeks. The go…
Sponsor: University of Bern • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:35 UTC